These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23270564)

  • 1. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.
    Brunello E; Brunelli M; Bogina G; Caliò A; Manfrin E; Nottegar A; Vergine M; Molino A; Bria E; Massari F; Tortora G; Cingarlini S; Pedron S; Chilosi M; Zamboni G; Miller K; Martignoni G; Bonetti F
    J Exp Clin Cancer Res; 2012 Dec; 31(1):103. PubMed ID: 23270564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
    Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
    Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
    Reis-Filho JS; Simpson PT; Turner NC; Lambros MB; Jones C; Mackay A; Grigoriadis A; Sarrio D; Savage K; Dexter T; Iravani M; Fenwick K; Weber B; Hardisson D; Schmitt FC; Palacios J; Lakhani SR; Ashworth A
    Clin Cancer Res; 2006 Nov; 12(22):6652-62. PubMed ID: 17121884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
    Meng H; Chen R; Li W; Xu L; Xu L
    Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M; Järvinen P; Isola J
    Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
    Durbecq V; Di Leo A; Cardoso F; Rouas G; Leroy JY; Piccart M; Larsimont D
    Breast Cancer Res Treat; 2003 Feb; 77(3):199-204. PubMed ID: 12602919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.
    Rosenthal SI; Depowski PL; Sheehan CE; Ross JS
    Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):40-6. PubMed ID: 11893034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
    Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
    Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.
    Singhi AD; Cimino-Mathews A; Jenkins RB; Lan F; Fink SR; Nassar H; Vang R; Fetting JH; Hicks J; Sukumar S; De Marzo AM; Argani P
    Mod Pathol; 2012 Mar; 25(3):378-87. PubMed ID: 22056952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
    Tanner M; Hollmén M; Junttila TT; Kapanen AI; Tommola S; Soini Y; Helin H; Salo J; Joensuu H; Sihvo E; Elenius K; Isola J
    Ann Oncol; 2005 Feb; 16(2):273-8. PubMed ID: 15668283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status.
    Monaco SE; Rodriguez EF; Mahaffey AL; Dacic S
    Am J Clin Pathol; 2016 Jan; 145(1):55-61. PubMed ID: 26712871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.